Published in Stem Cells Int on June 28, 2015
Influence of age on rat bone-marrow mesenchymal stem cells potential. Sci Rep (2015) 0.83
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
mTOR signaling in growth control and disease. Cell (2012) 29.21
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol (2004) 12.12
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature (2006) 11.86
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol (2012) 4.77
AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res (2009) 4.50
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J (2009) 4.12
Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov (2011) 4.05
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood (2009) 3.02
Total body irradiation selectively induces murine hematopoietic stem cell senescence. Blood (2005) 2.82
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov (2011) 2.77
mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science (2013) 2.71
Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression. Cell Stem Cell (2012) 2.15
mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell (2012) 2.06
Antileukemic activity of rapamycin in acute myeloid leukemia. Blood (2004) 2.03
The mTOR pathway: a new target in cancer therapy. Curr Cancer Drug Targets (2010) 1.68
Maintenance of hematopoietic stem cells through regulation of Wnt and mTOR pathways. Nat Med (2012) 1.58
The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res (2012) 1.54
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res (2009) 1.42
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia (2011) 1.37
Inhibition of p38 mitogen-activated protein kinase promotes ex vivo hematopoietic stem cell expansion. Stem Cells Dev (2011) 1.09
Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br J Cancer (2012) 1.09
Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. Bioorg Med Chem Lett (2010) 1.06
Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT. Clin Cancer Res (2014) 1.05
Mammalian target of rapamycin is required for thrombopoietin-induced proliferation of megakaryocyte progenitors. Stem Cells (2005) 1.03
Rapamycin enhances long-term hematopoietic reconstitution of ex vivo expanded mouse hematopoietic stem cells by inhibiting senescence. Transplantation (2014) 0.98
Mouse gene targeting reveals an essential role of mTOR in hematopoietic stem cell engraftment and hematopoiesis. Haematologica (2013) 0.94
Pleiotropic roles of mTOR complexes in haemato-lymphopoiesis and leukemogenesis. J Biochem (2014) 0.82
Catalase inhibits ionizing radiation-induced apoptosis in hematopoietic stem and progenitor cells. Stem Cells Dev (2015) 0.78
MiR-34a modulates ionizing radiation-induced senescence in lung cancer cells. Oncotarget (2017) 0.75
MiR-34a modulates ionizing radiation-induced senescence in lung cancer cells. Oncotarget (2017) 0.75
[Retrospective analysis of 86 patients with cytopenia during pregnancy]. Zhonghua Xue Ye Xue Za Zhi (2014) 0.75
[Plasma microRNA profile in immune thrombocytopenia: screening and verification]. Zhonghua Yi Xue Za Zhi (2014) 0.75